Nicolas Dif

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Brigitta G. Baumert, Monika E. Hegi, Martin J. van den Bent et al. · The Lancet Oncology · 2016 · 498 citations · Full text

Medicine, Oncology, Pharmacology +16

Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – The LORD study

Lotte E. Elshof, Konstantinos Tryfonidis, Leen Slaets et al. · European Journal of Cancer · 2015 · 380 citations · Full text

Medicine, Oncology, Breast Oncology +12

The Transcription of FOXO Genes Is Stimulated by FOXO3 and Repressed by Growth Factors

Ahmed Essaghir, Nicolas Dif, Catherine Y. Marbehant et al. · Journal of Biological Chemistry · 2009 · 220 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +14

Insulin activates human sterol-regulatory-element-binding protein-1c (SREBP-1c) promoter through SRE motifs

Nicolas Dif, Vanessa Euthine, Estelle Gonnet et al. · Biochemical Journal · 2006 · 150 citations · Full text

Life Sciences, Endocrinology, Molecular Biology +17

Regulation of SREBP-1 expression and transcriptional action on HKII and FAS genes during fasting and refeeding in rat tissues

Yvan Gosmain, Nicolas Dif, V. Berbe et al. · Journal of Lipid Research · 2005 · 129 citations · Full text

Life Sciences, Biochemistry, Nutritional Sciences +17